



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JAN 29 2003

RECEIVED

Application of: Catherine GUENTHER

Group Art Unit: 1636

Serial No.: 09/811,361

Examiner: Qian, Celine X

Filed: March 16, 2001

Attorney Docket No.: R-125

For: TRANSGENIC MICE CONTAINING RETINA-SPECIFIC NUCLEAR RECEPTOR
GENE DISRUPTIONS

AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

#17/C
Hita
1-29-03

Sir:

In response to the Office Action dated October 23, 2002, in connection with the above-identified application, Applicants respectfully request entry and consideration of the following amendments and remarks.

THE AMENDMENTS

In the claims:

Please cancel claims 11-16 and 25-37, previously withdrawn from consideration by the Examiner, which claims are drawn to non-elected inventions.

Please cancel claims 38-48 and claim 50.

Please add new claims 51-56 as follows.

C. 51. (New) A transgenic mouse whose genome comprises a disruption in an endogenous retina-specific nuclear receptor gene, wherein the transgenic mouse lacks production of functional retina-specific nuclear receptor and exhibits an eye abnormality.

52. (New) The transgenic mouse of claim 51, wherein the eye abnormality is retinal dysplasia.